Turtle Creek Wealth Advisors LLC Has $4.74 Million Stock Holdings in AbbVie Inc. $ABBV

Turtle Creek Wealth Advisors LLC increased its position in AbbVie Inc. (NYSE:ABBV) by 70.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,751 shares of the company’s stock after buying an additional 8,559 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in AbbVie were worth $4,741,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Chelsea Counsel Co. bought a new position in shares of AbbVie during the 3rd quarter worth approximately $26,000. Westend Capital Management LLC bought a new position in shares of AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter valued at approximately $31,000. WestEnd Advisors LLC lifted its holdings in AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Finally, Caitlin John LLC purchased a new position in AbbVie in the third quarter worth $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre pharmaceutical manufacturing campus in Durham, NC — its largest-ever single-site capital investment — which management says will add advanced, AI-enabled production capacity for immunology, neuroscience and oncology drugs and create hundreds of jobs; investors view this as a long-term capacity and supply-chain strengthening move. Read More.
• Positive Sentiment: Analyst sentiment turned more constructive: Canaccord initiated coverage with a Strong Buy / $262 price target, which supports upside expectations and likely helped buying interest after the campus announcement. Read More.
• Neutral Sentiment: AbbVie struck an exclusive licensing deal with Haisco to develop pain medicines (AbbVie will own development/manufacturing/commercial rights) — a potentially positive medium-term pipeline expansion, but impact depends on development milestones and commercialization timing. Read More.
• Neutral Sentiment: Investors are also watching upcoming Q1 earnings (Apr. 29) and consensus estimates; previews and models are circulating (Zacks and others) and could re-rate the name depending on results vs. guidance. Read More.
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) BLA, citing manufacturing-process concerns; the agency did not request new clinical studies but requires AbbVie to resolve manufacturing questions before approval — this delays a potential new product launch and creates near-term revenue uncertainty for the neurotoxin program. Read More.
• Negative Sentiment: Regulatory focus on manufacturing (FDA requests for additional information / manufacturing concerns highlighted in multiple reports) increases scrutiny on AbbVie’s production controls and could raise near-term remediation costs or timelines. AbbVie says it is well-positioned to address the FDA’s comments, but the issue tempers enthusiasm until resolved. Read More.

Insider Transactions at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of several research analyst reports. Barclays initiated coverage on AbbVie in a research report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price objective on the stock. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Citigroup lowered their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, Evercore dropped their price objective on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.19.

AbbVie Stock Performance

AbbVie stock opened at $200.97 on Friday. The stock has a market cap of $355.34 billion, a P/E ratio of 85.15, a PEG ratio of 0.72 and a beta of 0.38. AbbVie Inc. has a fifty-two week low of $176.11 and a fifty-two week high of $244.81. The firm’s fifty day moving average price is $217.33 and its 200-day moving average price is $222.62.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 earnings per share. The firm’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts predict that AbbVie Inc. will post 14.22 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.